Literature DB >> 15726615

Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.

Roberto Persiani1, Domenico D'Ugo, Stefano Rausei, Daniel Sermoneta, Carlo Barone, Carmelo Pozzo, Riccardo Ricci, Giuseppe La Torre, Aurelio Picciocchi.   

Abstract

BACKGROUND AND OBJECTIVES: Neoadjuvant chemotherapy is increasingly considered an effective treatment option for patients with gastric carcinoma. Aim of the study is to evaluate the prognostic significance of the pathological response and of known prognostic factors in a group of accurately staged locally advanced gastric cancer (LAGC) patients.
METHODS: Thirty-three patients with LAGC, staged by laparoscopy, underwent D2-gastrectomy after preoperative chemotherapy. Survival was calculated by Kaplan-Meier method and differences were assessed by the Log-rank and Breslow test. Multivariate analysis was performed using the Cox proportional hazard model in backward stepwise regression.
RESULTS: Curative resection (R0) was achieved in 81.8% of patients. A complete or subtotal pathological response was documented in 3 and 6%, respectively. Nineteen out of thirty-three (57.6%) patients were alive and 16 of them were free of relapse at last follow-up. Survival rates were 81, 67, and 59% at 12, 24, and 36 months, respectively. At univariate and multivariate analysis, only R0 resection was found to be an independent prognostic factor.
CONCLUSIONS: In the current study, R0 resection is the most important prognostic factor for resectable LAGC; according to our results we feel encouraged to consider neoadjuvant chemotherapy a promising modality for increasing the R0-percentage of gastric carcinoma patients who could benefit from a curative surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726615     DOI: 10.1002/jso.20207

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  13 in total

1.  Neoadjuvant chemotherapy for locally advanced gastric cancer: With or without radiation.

Authors:  Ai-Wen Wu; Jia-Fu Ji
Journal:  World J Gastrointest Surg       Date:  2012-02-27

2.  A decade in gastric cancer curative surgery: Evidence of progress (1999-2009).

Authors:  Stefano Rausei; Gianlorenzo Dionigi; Francesca Rovera; Luigi Boni; Caterina Valerii; Luisa Giavarini; Francesco Frattini; Renzo Dionigi
Journal:  World J Gastrointest Surg       Date:  2012-03-27

Review 3.  Proteomic and metabolic prediction of response to therapy in gastric cancer.

Authors:  Michaela Aichler; Birgit Luber; Florian Lordick; Axel Walch
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

4.  R0 resection in the treatment of gastric cancer: room for improvement.

Authors:  Alberto Biondi; Roberto Persiani; Ferdinando Cananzi; Marco Zoccali; Vincenzo Vigorita; Andrea Tufo; Domenico D'Ugo
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

5.  Clinicopathological features and outcomes of patients with gastric cancer: a single-center experience.

Authors:  Fatih Selcukbiricik; Evin Buyukunal; Deniz Tural; Mustafa Ozguroglu; Fuat Demirelli; Suheyla Serdengecti
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

Review 6.  Towards curative therapy in gastric cancer: Faraway, so close!

Authors:  Marília Cravo; Catarina Fidalgo; Rita Garrido; Tânia Rodrigues; Gonçalo Luz; Carolina Palmela; Marta Santos; Fábio Lopes; Rui Maio
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

7.  ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system.

Authors:  Ziyu Li; Yinkui Wang; Fei Shan; Xiangji Ying; Zhouqiao Wu; Kan Xue; Rulin Miao; Yan Zhang; Jiafu Ji
Journal:  Gastric Cancer       Date:  2018-05-10       Impact factor: 7.370

8.  FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer.

Authors:  Wenjun Chen; Jianguo Shen; Tao Pan; Wenxian Hu; Zinong Jiang; Xiaoming Yuan; Linbo Wang
Journal:  Exp Ther Med       Date:  2013-12-13       Impact factor: 2.447

9.  Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center.

Authors:  Zhen Sun; Rui-Juan Zhu; Gui-Fang Yang; Yan Li
Journal:  ScientificWorldJournal       Date:  2014-07-17

Review 10.  Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.

Authors:  Cristina Díaz Del Arco; Luis Ortega Medina; Lourdes Estrada Muñoz; Soledad García Gómez de Las Heras; Mª Jesús Fernández Aceñero
Journal:  Histol Histopathol       Date:  2021-02-10       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.